AZNAstraZenecaRunning, no new patients
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 506 (final count)
- Started
- Jun 22, 2021
- Main results expected
- Feb 8, 2024
- Fully finished
- May 26, 2027
- Results posted
- May 16, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)
Measured over: From first dose (Day 1) to progression of disease (up to 2 years 7 months)
Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)
Measured over: At 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04739761 · record last updated 2026-08-11 · checked 2026-11-09 15:47 UTC